Market share of Novo Nordisk’s Tresiba grew twice more in 2nd quarter

The market share of a Novo Nordisk Pharma Korea’s next-generation basal insulin, Tresiba Flextouch Inj(generic name: insulin degludec), was increased by double in the 2^nd quarter compared to the one of the 1^st quarter in 2016.

According to data of IMS, a pharmaceutical market research company, Tresiba was known to take 13.1% of the market share in the domestic basal insulin market as of the 2...